Saltar al contenido
Merck

Glipizide suppresses embryonic vasculogenesis and angiogenesis through targeting natriuretic peptide receptor A.

Experimental cell research (2015-04-01)
Quliang Gu, Chaojie Wang, Guang Wang, Zhe Han, Yan Li, Xiaoyu Wang, Jiangchao Li, Cuiling Qi, Tao Xu, Xuesong Yang, Lijing Wang
RESUMEN

Glipizide, a second-generation sulfonylurea, has been widely used for the treatment of type 2 diabetes. However, it is controversial whether or not glipizide would affect angiogenesis or vasculogenesis. In the present study, we used early chick embryo model to investigate the effect of glipizide on angiogenesis and vasculogenesis, which are the two major processes for embryonic vasculature formation as well as tumor neovascularization. We found that Glipizide suppressed both angiogenesis in yolk-sac membrane (YSM) and blood island formation during developmental vasculogenesis. Glipizide did not affect either the process of epithelial to mesenchymal transition (EMT) or mesoderm cell migration. In addition, it did not interfere with separation of smooth muscle cell progenitors from hemangioblasts. Moreover, natriuretic peptide receptor A (NPRA) has been identified as the putative target for glipizide׳s inhibitory effect on vasculogenesis. When NPRA was overexpressed or activated, blood island formation was reduced. NPRA signaling may play a crucial role in the effect of glipizide on vasculogenesis during early embryonic development.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
DAPI, for nucleic acid staining
Número de referencia del producto (SKU)
Tamaño de envase
Disponibilidad
Precio
Cantidad
Sigma-Aldrich
8-Bromoguanosine 3′,5′-cyclic monophosphate sodium salt, ≥98% (HPLC), powder
Número de referencia del producto (SKU)
Tamaño de envase
Disponibilidad
Precio
Cantidad
Sigma-Aldrich
Glipizide, solid
Número de referencia del producto (SKU)
Tamaño de envase
Disponibilidad
Precio
Cantidad